Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Mireia Pesarrodona; Toni Jauset; Zamira V. Díaz-Riascos; Alejandro Sánchez-Chardi; Marie Eve Beaulieu; Joaquin Seras-Franzoso; Laura Sánchez-García; Ricardo Baltà-Foix; Sandra Mancilla; Yolanda Fernández; Ursula Rinas; Simó Schwartz; Laura Soucek; Antonio Villaverde; Ibane Abasolo; Esther Vázquez

doi:10.1002/advs.201900849

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz-Riascos, Alejandro Sánchez-Chardi, Marie Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez

Research output: Contribution to journal › Article › Research

13 Citations (Scopus)

Abstract

© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

Original language	English
Article number	1900849
Journal	Advanced Science
Volume	6
DOIs	https://doi.org/10.1002/advs.201900849
Publication status	Published - 1 Sep 2019

Keywords

biofabrication
cancer therapy
functional amyloids
inclusion bodies
protein drug release

Access to Document

10.1002/advs.201900849

Fingerprint Dive into the research topics of 'Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies'. Together they form a unique fingerprint.

Cite this

Pesarrodona, M., Jauset, T., Díaz-Riascos, Z. V., Sánchez-Chardi, A., Beaulieu, M. E., Seras-Franzoso, J., Sánchez-García, L., Baltà-Foix, R., Mancilla, S., Fernández, Y., Rinas, U., Schwartz, S., Soucek, L., Villaverde, A., Abasolo, I., & Vázquez, E. (2019). Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced Science, 6, [1900849]. https://doi.org/10.1002/advs.201900849

Pesarrodona, Mireia ; Jauset, Toni ; Díaz-Riascos, Zamira V. ; Sánchez-Chardi, Alejandro ; Beaulieu, Marie Eve ; Seras-Franzoso, Joaquin ; Sánchez-García, Laura ; Baltà-Foix, Ricardo ; Mancilla, Sandra ; Fernández, Yolanda ; Rinas, Ursula ; Schwartz, Simó ; Soucek, Laura ; Villaverde, Antonio ; Abasolo, Ibane ; Vázquez, Esther. / Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. In: Advanced Science. 2019 ; Vol. 6.

@article{a1f0014f3ffe48d1acfb00505475cbf5,

title = "Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies",

abstract = "{\textcopyright} 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.",

keywords = "biofabrication, cancer therapy, functional amyloids, inclusion bodies, protein drug release",

author = "Mireia Pesarrodona and Toni Jauset and D{\'i}az-Riascos, {Zamira V.} and Alejandro S{\'a}nchez-Chardi and Beaulieu, {Marie Eve} and Joaquin Seras-Franzoso and Laura S{\'a}nchez-Garc{\'i}a and Ricardo Balt{\`a}-Foix and Sandra Mancilla and Yolanda Fern{\'a}ndez and Ursula Rinas and Sim{\'o} Schwartz and Laura Soucek and Antonio Villaverde and Ibane Abasolo and Esther V{\'a}zquez",

year = "2019",

month = sep,

day = "1",

doi = "10.1002/advs.201900849",

language = "English",

volume = "6",

journal = "Advanced Science",

issn = "2198-3844",

}

Pesarrodona, M, Jauset, T, Díaz-Riascos, ZV, Sánchez-Chardi, A, Beaulieu, ME, Seras-Franzoso, J, Sánchez-García, L, Baltà-Foix, R, Mancilla, S, Fernández, Y, Rinas, U, Schwartz, S, Soucek, L , Villaverde, A, Abasolo, I & Vázquez, E 2019, 'Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies', Advanced Science, vol. 6, 1900849. https://doi.org/10.1002/advs.201900849

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. / Pesarrodona, Mireia; Jauset, Toni; Díaz-Riascos, Zamira V.; Sánchez-Chardi, Alejandro; Beaulieu, Marie Eve; Seras-Franzoso, Joaquin; Sánchez-García, Laura; Baltà-Foix, Ricardo; Mancilla, Sandra; Fernández, Yolanda; Rinas, Ursula; Schwartz, Simó; Soucek, Laura ; Villaverde, Antonio; Abasolo, Ibane; Vázquez, Esther.

In: Advanced Science, Vol. 6, 1900849, 01.09.2019.

Research output: Contribution to journal › Article › Research

TY - JOUR

T1 - Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

AU - Pesarrodona, Mireia

AU - Jauset, Toni

AU - Díaz-Riascos, Zamira V.

AU - Sánchez-Chardi, Alejandro

AU - Beaulieu, Marie Eve

AU - Seras-Franzoso, Joaquin

AU - Sánchez-García, Laura

AU - Baltà-Foix, Ricardo

AU - Mancilla, Sandra

AU - Fernández, Yolanda

AU - Rinas, Ursula

AU - Schwartz, Simó

AU - Soucek, Laura

AU - Villaverde, Antonio

AU - Abasolo, Ibane

AU - Vázquez, Esther

PY - 2019/9/1

Y1 - 2019/9/1

N2 - © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

AB - © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

KW - biofabrication

KW - cancer therapy

KW - functional amyloids

KW - inclusion bodies

KW - protein drug release

U2 - 10.1002/advs.201900849

DO - 10.1002/advs.201900849

M3 - Article

C2 - 31559131

VL - 6

JO - Advanced Science

JF - Advanced Science

SN - 2198-3844

M1 - 1900849

ER -